Biotech · Private company
Goldfinch Bio, Inc.
Track this companyFree. Adds Goldfinch Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- GFB-887Phase 2 · Kidney DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- GFB-024Phase 1 · Kidney DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- GFB-887Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- Diabetic Nephropathy (DN)Glomerulosclerosis, Focal SegmentalClinicalTrials.gov · fetched Nov 12, 2026
- FSGS/TR-MCDGlomerulosclerosis, Focal SegmentalClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney DiseasesPHASE2 · TERMINATED · started Jul 27, 2021ClinicalTrials.gov NCT04950114 · fetched Nov 12, 2026
- First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 DiabetesPHASE1 · COMPLETED · started May 5, 2021ClinicalTrials.gov NCT04880291 · fetched Nov 12, 2026
- A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change DiseasePHASE2 · TERMINATED · started Jul 28, 2020ClinicalTrials.gov NCT04387448 · fetched Nov 12, 2026
- A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)TERMINATED · started Dec 20, 2019ClinicalTrials.gov NCT04235621 · fetched Nov 12, 2026
- FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy SubjectsPHASE1 · COMPLETED · started May 29, 2019ClinicalTrials.gov NCT03970122 · fetched Nov 12, 2026